These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 21135887)

  • 1. Preclinical development of molecular-targeted agents for cancer.
    Ocana A; Pandiella A; Siu LL; Tannock IF
    Nat Rev Clin Oncol; 2010 Dec; 8(4):200-9. PubMed ID: 21135887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The next generation: new chemotherapy agents for the 1990s.
    Galassi A
    Semin Oncol Nurs; 1992 May; 8(2):83-94. PubMed ID: 1621007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical models for defining efficacy of drug combinations: mapping the road to the clinic.
    Gitler MS; Monks A; Sausville EA
    Mol Cancer Ther; 2003 Sep; 2(9):929-32. PubMed ID: 14555712
    [No Abstract]   [Full Text] [Related]  

  • 4. High drug attrition rates--where are we going wrong?
    Hutchinson L; Kirk R
    Nat Rev Clin Oncol; 2011 Mar; 8(4):189-90. PubMed ID: 21448176
    [No Abstract]   [Full Text] [Related]  

  • 5. The use of targeted mouse models for preclinical testing of novel cancer therapeutics.
    Olive KP; Tuveson DA
    Clin Cancer Res; 2006 Sep; 12(18):5277-87. PubMed ID: 17000660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Future directions of anticancer drug development in Japan].
    Akaza H; Kawai K; Tsuruo T; Tsukagoshi S; Aiba K; Shimada Y; Kakeji Y; Ishikawa H; Ikeda T; Nakamura S; Tamura T; Yamamoto N; Isonishi S; Hinotsu S; Hirose M; Katsura J
    Gan To Kagaku Ryoho; 2008 Feb; 35(2):351-60. PubMed ID: 18281781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prince and the pauper. A tale of anticancer targeted agents.
    Dueñas-González A; García-López P; Herrera LA; Medina-Franco JL; González-Fierro A; Candelaria M
    Mol Cancer; 2008 Oct; 7():82. PubMed ID: 18947424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical screening methods in cancer.
    Kumar S; Bajaj S; Bodla RB
    Indian J Pharmacol; 2016; 48(5):481-486. PubMed ID: 27721530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of molecularly targeted anticancer therapies: an Eli Lilly and Company perspective.
    Perry WL; Weitzman A
    Clin Adv Hematol Oncol; 2005 Mar; 3(3):199-202, 237-8. PubMed ID: 16166991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy.
    Di Francia R; De Monaco A; Saggese M; Iaccarino G; Crisci S; Frigeri F; De Filippi R; Berretta M; Pinto A
    Curr Cancer Drug Targets; 2018; 18(5):499-511. PubMed ID: 28183252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP inhibitors for cancer therapy.
    Curtin NJ
    Expert Rev Mol Med; 2005 Mar; 7(4):1-20. PubMed ID: 15836799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
    Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
    Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges in pre-clinical testing of anti-cancer drugs in cell culture and in animal models.
    HogenEsch H; Nikitin AY
    J Control Release; 2012 Dec; 164(2):183-6. PubMed ID: 22446384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Harnessing the predictive power of preclinical models for oncology drug development.
    Honkala A; Malhotra SV; Kummar S; Junttila MR
    Nat Rev Drug Discov; 2022 Feb; 21(2):99-114. PubMed ID: 34702990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the preclinical testing of cancer therapeutic hypotheses.
    Caponigro G; Sellers WR
    Nat Rev Drug Discov; 2011 Mar; 10(3):179-87. PubMed ID: 21358737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detecting the Potential Pharmacological Synergy of Drug Combination by Viability Assays In Vitro.
    Gibbs BK; Sourbier C
    Methods Mol Biol; 2018; 1709():129-137. PubMed ID: 29177656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular targets in the discovery and development of novel antimetastatic agents: current progress and future prospects.
    Wong MS; Sidik SM; Mahmud R; Stanslas J
    Clin Exp Pharmacol Physiol; 2013 May; 40(5):307-19. PubMed ID: 23534409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Finding their groove; bifunctional molecules arrest growth of cancer cells.
    Mapp AK
    Chem Biol; 2004 Nov; 11(11):1480-2. PubMed ID: 15555997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery.
    Ruggeri BA; Camp F; Miknyoczki S
    Biochem Pharmacol; 2014 Jan; 87(1):150-61. PubMed ID: 23817077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights into drug development for pediatric solid tumors: what preclinical data justify clinical trials in pediatric cancer?
    Houghton PJ
    Expert Rev Anticancer Ther; 2013 Oct; 13(10):1135-8. PubMed ID: 24093514
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.